116 results on '"Kaikita, Koichi"'
Search Results
2. Increasing baseline aortic valve peak flow velocity is associated with progression of aortic valve stenosis in osteoporosis patients—a possible link to low vitamin D status.
- Author
-
Tsuruda, Toshihiro, Funamoto, Taro, Suzuki, Chiyoko, Yamamura, Yoshimasa, Nakai, Michikazu, Chosa, Etsuo, and Kaikita, Koichi
- Abstract
Purpose: The purpose of this study was to investigate the morphological characteristics of the aortic valve and identify factors associated with the progression of aortic valve stenosis (AS) in osteoporosis patients. Methods: In this single-center prospective cohort study, we recruited 10 patients (mean age: 75 ± 7 years, 90% female) who were taking anti-resorptive medicines at the outpatient clinic of University of Miyazaki Hospital, Japan. Baseline assessments, including transthoracic echocardiogram, blood sampling, and dual energy X-ray absorptiometry, were performed. Follow-up assessments were conducted at 6, 12, 18, and 24 months. Results: During the 2-year follow-up, three patients with aortic valve peak flow velocity (AV PFV) ≥2 m/s at baseline developed moderate AS, which is defined as AV PFV ≥3 m/s. However, seven patients with AV PFV <2 m/s did not exhibit any progression of AS. There were significant variations in terms of bone mineral density, T-score values, and biomarkers associated with bone turnover (i.e., bone alkaline phosphatase, tartrate-resistance acid phosphatase-5b) among the enrolled patients, but none of these factors were found to be associated with the progression of AS. All patients exhibited low vitamin D status, with a median level of 16.1 ng/mL (25
th percentile, 9.7 ng/mL; 75th percentile, 23 ng/mL). The baseline levels of AV PFV values were negatively correlated with 25-hydroxyvitamin D levels, determined by univariate linear regression analysis (beta coefficient = -0.756, 95% confidence interval, -0.136 ̶ -0.023, p = 0.011). Conclusion: Our data suggest that low vitamin D status might be a potential risk factor for the progression of AS in osteoporosis patients undergoing treatment with anti-resorptive medicines. Summary: Elderly patients with osteoporosis patients exhibited a subset of aortic valve stenosis. Our data suggest that the baseline aortic valve peak flow velocity predicts the progression of aortic valve stenosis, and there might be an association between the progression and the co-existing low vitamin D status in these patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention.
- Author
-
Nakanishi, Nobuhiro, Kaikita, Koichi, Ishii, Masanobu, Kuyama, Naoto, Tabata, Noriaki, Ito, Miwa, Yamanaga, Kenshi, Fujisue, Koichiro, Hoshiyama, Tadashi, Kanazawa, Hisanori, Hanatani, Shinsuke, Sueta, Daisuke, Takashio, Seiji, Arima, Yuichiro, Araki, Satoshi, Usuku, Hiroki, Nakamura, Taishi, Yamamoto, Eiichiro, Soejima, Hirofumi, and Matsushita, Kenichi
- Abstract
Although the Japanese high bleeding risk criteria (J-HBR) were established to predict bleeding risk in patients undergoing percutaneous coronary intervention (PCI), the thrombogenicity in the J-HBR status remains unknown. Here, we examined the relationships among J-HBR status, thrombogenicity and bleeding events. This study was a retrospective analysis of 300 consecutive patients who underwent PCI. Blood samples obtained on the day of PCI were used in the total thrombus-formation analysis system (T-TAS) to investigate the thrombus-formation area under the curve (AUC; PL
18 -AUC10 for platelet chip; AR10 -AUC30 for atheroma chip). The J-HBR score was calculated by adding 1 point for any major criterion and 0.5 point for any minor criterion. We assigned patients to three groups based on J-HBR status: a J-HBR-negative group (n = 80), a low score J-HBR-positive group (positive/low, n = 109), and a high score J-HBR-positive group (positive/high, n = 111). The primary end point was the 1-year incidence of bleeding events defined by the Bleeding Academic Research Consortium types 2, 3, or 5. Both PL18 -AUC10 and AR10 -AUC30 levels were lower in the J-HBR-positive/high group than the negative group. Kaplan–Meier analysis showed worse 1-year bleeding event-free survival in the J-HBR-positive/high group compared with the negative group. In addition, both T-TAS levels in J-HBR positivity were lower in those with bleeding events than in those without bleeding events. In multivariate Cox regression analyses, the J-HBR-positive/high status was significantly associated with 1-year bleeding events. In conclusion, the J-HBR-positive/high status could reflect low thrombogenicity as measured by T-TAS and high bleeding risk in patients undergoing PCI. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Relationship between coronary artery calcium score and bleeding events after percutaneous coronary intervention in chronic coronary syndrome.
- Author
-
Komaki, Soichi, Ishii, Masanobu, Kaichi, Ryota, Takae, Masafumi, Mori, Takayuki, Toida, Reiko, Kurogi, Kazumasa, Matsuura, Yunosuke, Yamamoto, Nobuyasu, Tsujita, Kenichi, Tsuruda, Toshihiro, and Kaikita, Koichi
- Subjects
CORONARY artery calcification ,PERCUTANEOUS coronary intervention ,HEMORRHAGE ,SYNDROMES ,CONSORTIA - Abstract
The relationship between coronary artery calcium (CAC) and bleeding events after percutaneous coronary intervention (PCI) in patients with chronic coronary syndrome (CCS) is not well established. This study aimed to examine the association between CAC scores and clinical outcomes after PCI in patients with CCS. This retrospective observational study included 295 consecutive patients who underwent multidetector computer tomography and were scheduled for their first elective PCI. Patients were categorized into two groups based on the CAC scores (low: ≤ 400 or high: > 400). The bleeding risk was evaluated using the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria. The primary clinical outcome was a major bleeding event within 1 year after PCI, defined as Bleeding Academic Research Consortium (BARC) 3 or 5. The high CAC score group had a higher proportion of patients meeting the ARC-HBR criteria than the low CAC score group (52.7% vs. 31.3%, p < 0.001). Kaplan–Meier survival analysis showed that the incidence of major bleeding events was higher in the high CAC score group as compared to the low CAC score group (p < 0.001). Furthermore, multivariate Cox regression anal ysis revealed that a high CAC score was an independent determinant of major bleeding events during the first year after PCI. A high CAC score is significantly associated with the incidence of major bleeding events after PCI in CCS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients.
- Author
-
Matsuo, Osamu, Ishii, Masanobu, Kaikita, Koichi, Morinaga, Jun, Miyamura, Fumiya, Matsumoto, Shiro, Tsujita, Kenichi, and Nakamura, Kimitoshi
- Subjects
FIBRINOLYTIC agents ,CENTRAL venous pressure ,PEDIATRIC therapy ,CARDIAC catheterization ,CARDIAC surgery - Abstract
Background: There is no consensus regarding thromboprophylaxis after Fontan procedure, and novel tools to assess thrombogenicity are needed to establish optimal thromboprophylaxis. The Total Thrombus-formation Analysis System (T-TAS) was developed for the quantitative analysis of thrombus formation using microchips with thrombogenic surfaces. This prospective study evaluated the utility of T-TAS in the assessment of thrombogenicity in pediatric Fontan patients. Methods and Results: The participants included 20 consecutive Fontan patients who underwent cardiac catheterization and 30 healthy controls. Blood samples collected without and with antithrombotic therapy (aspirin or aspirin and warfarin) were used for T-TAS to compute the area under the curve (AUC) in the atheroma (AR
10 -AUC30 ) and platelet (PL18 -AUC10 ) chips. A higher AUC indicates higher thrombogenicity. T-TAS values showed that patients in the Fontan group without antithrombotic therapy had lower thrombogenicity than those in the control group [PL18 -AUC10 , median (interquartile range) 356 (313–394) vs. 408 (392–424); AR10 -AUC30 , median (interquartile range) 1270 (1178–1351) vs. 1382 (1338–1421)]. Aspirin and warfarin therapies significantly decreased PL18 -AUC10 and AR10 -AUC30 , respectively, compared with those of patients without antithrombotic therapy (P < 0.001 for each comparison). Subgroup analysis divided by low (< 9 mmHg) or high (≥ 9 mmHg) central venous pressure (CVP) showed that CVP affects the reduction in AR10 -AUC30 with antithrombotic therapy. Conclusions: T-TAS may be a useful tool for monitoring thrombogenicity and antithrombotic therapy in Fontan patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Analysis of Mechanisms for Increased Blood Pressure Variability in Rats Continuously Infused with Angiotensin II.
- Author
-
Jiang, Danfeng, Matsuzaki, Minami, Kawagoe, Yukiko, Kitamura, Kazuo, Tsuruda, Toshihiro, Kaikita, Koichi, Asada, Yujiro, and Kato, Johji
- Subjects
BLOOD pressure ,ANGIOTENSIN II ,THORACIC aorta ,ORAL drug administration ,BAROREFLEXES - Abstract
Objective. We reported that rats infused with angiotensin II (Ang II) are not only a model of hypertension but also of augmented 24 h blood pressure variability (BPV). In this study, we examined the mechanisms for Ang II-induced BPV, focusing on BP, heart rate (HR), baroreceptor reflex sensitivity (BRS), and medial area of the aortic arch. Methods. Nine-week-old male Wistar rats were infused with subcutaneous 5.2 μ g/kg/h Ang II with or without oral administration with 30 mg/kg/day azelnidipine for 14 days. BP and HR were recorded every 15 min under an unrestrained condition by a radiotelemetry system, while BPV was evaluated by standard deviation of BP. BRS was quantified by a sequence analysis, and medial thickness of the aortic arch was measured by microscopic examination. Results. BPV increased at days 7 and 14 following continuous infusion of Ang II. Before the infusion, a positive correlation was found between BP and HR, but it became negative at day 7 and then weakened or disappeared at day 14. BRS was slightly impaired at day 7 and significantly lowered at day 14, a phenomenon accompanied by thickened medial area of the aortic arch in Ang II-infused rats. Those Ang II-induced alterations were all significantly attenuated by azelnidipine. Conclusions. The present findings suggest sequential changes in the mechanisms behind augmented BPV in rats continuously infused with Ang II over 14 days. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis.
- Author
-
Mitsuru Ishii, Masaharu Akao, Satoshi Yasuda, Koichi Kaikita, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Ishii, Mitsuru, Akao, Masaharu, Yasuda, Satoshi, Kaikita, Koichi, Ako, Junya, Matoba, Tetsuya, and Nakamura, Masato
- Published
- 2022
- Full Text
- View/download PDF
8. Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.
- Author
-
Arashi, Hiroyuki, Yamaguchi, Junichi, Hagiwara, Nobuhisa, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Kimura, Kazuo, Hirayama, Atsushi, Matsui, Kunihiko, and Ogawa, Hisao
- Published
- 2022
- Full Text
- View/download PDF
9. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
- Author
-
Naito, Ryo, Miyauchi, Katsumi, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Hagiwara, Nobuhisa, Kimura, Kazuo, Hirayama, Atsushi, Matsui, Kunihiko, and Ogawa, Hisao
- Published
- 2022
- Full Text
- View/download PDF
10. Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis.
- Author
-
Toida, Reiko, Uezono, Shigehiro, Komatsu, Hiroyuki, Toida, Tatsunori, Imamura, Akiko, Fujimoto, Shouichi, and Kaikita, Koichi
- Published
- 2022
- Full Text
- View/download PDF
11. Optical coherence tomography—versus intravascular ultrasound-guided stent expansion in calcified lesions.
- Author
-
Kurogi, Kazumasa, Ishii, Masanobu, Ikebe, Sou, Kaichi, Ryota, Mori, Takayuki, Komaki, Soichi, Yamamoto, Nobuyasu, Yamanaga, Kenshi, Arima, Yuichiro, Yamamoto, Eiichiro, Kaikita, Koichi, Matsushita, Kenichi, and Tsujita, Kenichi
- Abstract
Optical coherence tomography (OCT) has a higher resolution than intravascular ultrasound (IVUS) and enables a more precise evaluation of calcium severity. We investigated the impact of the imaging method (OCT versus IVUS) on stent expansion during intravascular imaging-guided percutaneous coronary intervention (PCI) in calcified lesions. In this single-center, retrospective, observational study, 145 lesions with moderate to severe calcification were divided into four groups: 40 IVUS-guided rotational atherectomy (RA), 38 IVUS-guided non-RA, 35 OCT-guided RA, and 32 OCT-guided non-RA. Lesions without pre-procedural intravascular imaging were excluded. OCT-guided RA was associated with greater stent expansion at the target calcium compared with IVUS-guided RA (median 88.0%, interquartile range [78.0–96.0] vs. 76.5% [71.0–84.3], P = 0.008). Furthermore, stent expansion in OCT-guided non-RA was similar to OCT-guided RA. OCT-guided RA used a larger burr compared to IVUS-guided RA (1.75 mm [1.50–2.0] vs. 1.50 mm [1.50–1.75], P = 0.004). In OCT-guided RA, the median minimum calcium thickness was significantly reduced from 800 (640–980) µm to 550 (350–680) µm (P < 0.001). There was no significant difference in the incidence of ischemia driven target lesion revascularization between the four groups (P = 0.37). By determining the indication and endpoint of lesion modification by RA based on the thickness of calcium, OCT-guided PCI was associated with significantly greater stent expansion compared with IVUS-guided PCI. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial.
- Author
-
Matsui, Kunihiko, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Hagiwara, Nobuhisa, Kimura, Kazuo, Hirayama, Atsushi, and Ogawa, Hisao
- Subjects
FIBRINOLYTIC agents ,KIDNEY transplantation ,KIDNEY physiology ,HEMORRHAGE ,SUBGROUP analysis (Experimental design) ,GLOMERULAR filtration rate - Abstract
Background: The success of antithrombotic therapies is assessed based on thrombotic and bleeding events. Simultaneously assessing both kinds of events might be challenging, and recurrent bleeding events are often ignored. We tried to confirm the effects of kidney function on outcome events in patients undergoing antithrombotic therapy.Methods: As a post hoc subgroup analysis of the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, a randomized clinical trial with a median follow-up of 36 months, patients were divided into high and low estimated glomerular filtration rate (eGFR) groups with a cutoff value of 50 mL/min. The cumulative incidence of bleeding and crude incidence of recurrent bleeding per 100 patient-years were calculated. We used the Cox regression model with multiple failure time data for recurrent bleeding events.Results: Among 2092 patients, 1386 (66.3%) showed high eGFR. The cumulative bleeding events per 100 patients at 1 year were 5.4 and 6.2 in the high and low eGFR groups, respectively. The difference continued to increase over time. The hazard ratio for time to the first bleeding event in the high eGFR group was 0.875 (95% confidence interval 0.701-1.090, p = .234) and that for the first composite event was 0.723 (95% confidence interval 0.603-0.867, p < .000). The recurrent bleeding events per 100 person-years were 11.3 and 15.3 in the high and low eGFR groups, respectively, with a rate ratio of 0.738 (95% confidence interval 0.615-0.886, p = .001). During the observation period, the risk of bleeding changed with time. It peaked soon after the study enrollment in both groups. It decreased continuously in the high eGFR group but remained high in the low eGFR group.Conclusions: We reaffirmed that kidney function affects bleeding events in patients on antithrombotic therapy, considering recurrent events. Patients should have detailed discussions with physicians regarding the possible bleeding events when continuing antithrombotic therapy, especially in patients with decreased kidney function.Trial Registration: UMIN Clinical Trials Registry, UMIN000016612 . ClinicalTrials.gov, NCT02642419 . Registered on 21 October 2015. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. East Asian variant aldehyde dehydrogenase type 2 genotype exacerbates ischemia/reperfusion injury with ST-elevation myocardial infarction in men: possible sex differences.
- Author
-
Ishida, Toshifumi, Arima, Yuichiro, Mizuno, Yuji, Harada, Eisaku, Yamashita, Takayoshi, Sueta, Daisuke, Sakamoto, Kenji, Suzuki, Satoru, Kaikita, Koichi, Yamada, Yoshihiro, Shimomura, Hideki, Oniki, Kentaro, Saruwatari, Junji, Hokimoto, Seiji, Yasue, Hirofumi, and Tsujita, Kenichi
- Subjects
ST elevation myocardial infarction ,ALDEHYDE dehydrogenase ,REPERFUSION injury ,MYOCARDIAL injury ,EAST Asians - Abstract
Mitochondrial aldehyde dehydrogenase 2 (ALDH2) detoxifies toxic aldehydes generated during ischemia/reperfusion (I/R) injury in ST-elevation myocardial infarction (STEMI). The deficient variant ALDH2 genotype (ALDH2*2) is prevalent among East Asians. Whether ALDH2*2 exacerbates I/R injury of in patients with STEMI is not known. The study subjects comprised 218 Japanese patients with STEMI (158 men and 60 women, mean age 67.9 ± 11.9) who underwent successful percutaneous coronary intervention. Of these, 120 (55.0%) were the carriers of variant ALDH2*2 and 98 (45.0%) those of wild ALDH2*1/*1 on genotyping. There were no differences in clinical characteristics between the ALDH2*2 and ALDH2*1/*1 group except lower alcohol habit (14.2% vs 46.3%, P < 0.001) in the ALDH2*2 group. The peak plasma levels of creatine phosphokinase myocardial binding (CKMB), a marker of myocardial injury, however, were significantly higher in the patients with ALDH2*2 than in those with ALDH2*1/*1 [a median 275.0 (175.8–407.5) vs 177.5 (126.9–344.3) U/L, P = 0.001] among men but not among women (P = 0.811). There was a significant interaction between men (male sex) and ALDH2*2 for I/R injury (χ2 = 4.425, P = 0.040). The variant ALDH2*2 was associated with more severe I/R injury than the wild ALDH2*1/*1 in STEMI patients in men with possible sex differences. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
- Author
-
Hirakawa, Kyoko, Yamamoto, Eiichiro, Takashio, Seiji, Hanatani, Shinsuke, Araki, Satoshi, Suzuki, Satoru, Kaikita, Koichi, Matsushita, Kenichi, Ogo, Takeshi, and Tsujita, Kenichi
- Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by chronic stenosis or obstruction of the pulmonary arteries due to thromboembolism. Although previous studies have shown untreated CTEPH has a poor prognosis, the establishment of gold-standard therapies including pulmonary endarterectomy, balloon pulmonary angioplasty (BPA), and medical therapy has improved hemodynamics and right ventricular function, leading to good long-term survival. BPA is an important therapy for patients with inoperable CTEPH, although the procedure is currently limited to specific institutions and operators. This review discusses the development of the rapidly evolving field of CTEPH that includes improvements in imaging modalities and advances in surgical and interventional techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.
- Author
-
Yasushi Matsuzawa, Kazuo Kimura, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Matsuzawa, Yasushi, Kimura, Kazuo, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, and Matoba, Tetsuya
- Published
- 2021
- Full Text
- View/download PDF
16. Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation.
- Author
-
Hidehira Fukaya, Junya Ako, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Tetsuya Matoba, Masato Nakamra, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Fukaya, Hidehira, Ako, Junya, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Matoba, Tetsuya, and Nakamra, Masato
- Subjects
ASPIRIN ,ATRIAL fibrillation ,CORONARY artery disease ,PHYSICIANS ,ANGINA pectoris ,FIBRINOLYTIC agents ,THROMBOSIS prevention ,THROMBOSIS ,RESEARCH ,COMBINATION drug therapy ,RESEARCH methodology ,NEUROTRANSMITTERS ,ANTICOAGULANTS ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,DRUGS ,PLATELET aggregation inhibitors ,DISEASE complications - Abstract
Objective: Patients with coronary artery disease (CAD) and atrial fibrillation (AF) can be treated with multiple antithrombotic therapies including antiplatelet and anticoagulant therapies; however, this has the potential to increase bleeding risk. Here, we aimed to evaluate the efficacy and safety of P2Y12 inhibitors and aspirin in patients also receiving anticoagulant therapy.Methods: We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician's discretion. The primary efficacy and safety end points, consistent with those of the AFIRE trial, were compared between P2Y12 inhibitors and aspirin groups. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularisation or death from any cause. The primary safety end point was major bleeding according to the International Society on Thrombosis and Haemostasis criteria.Results: A total of 1075 patients were included (P2Y12 inhibitor group, n=297; aspirin group, n=778). Approximately 60% of patients were administered proton pump inhibitors (PPIs) and there was no significant difference in PPI use in the groups. There were no significant differences in the primary end points between the groups (efficacy: HR 1.31; 95% CI 0.88 to 1.94; p=0.178; safety: HR 0.79; 95% CI 0.43 to 1.47; p=0.456).Conclusions: There were no significant differences in cardiovascular and bleeding events in patients with AF and stable CAD taking rivaroxaban with P2Y12 inhibitors or aspirin in the chronic phase.Trial Registration Number: UMIN000016612; NCT02642419. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study.
- Author
-
Atarashi, Hirotsugu, Uchiyama, Shinichiro, Inoue, Hiroshi, Kitazono, Takanari, Yamashita, Takeshi, Shimizu, Wataru, Ikeda, Takanori, Kamouchi, Masahiro, Kaikita, Koichi, Fukuda, Koji, Origasa, Hideki, and Shimokawa, Hiroaki
- Subjects
ISCHEMIC stroke ,ATRIAL fibrillation ,KIDNEY diseases ,RIVAROXABAN ,PROPENSITY score matching - Abstract
The EXPAND Study demonstrated the effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) in routine clinical practice in Japan. This sub-analysis was conducted to reveal the effectiveness and safety of rivaroxaban in Japanese NVAF patients according to baseline creatinine clearance (CrCl) levels and rivaroxaban doses in the EXPAND Study. We examined 6806 patients whose baseline CrCl data were available and classified them into 2 groups: normal renal function group with CrCl ≥ 50 mL/min (n = 5326, 78%) and renal dysfunction group with CrCl < 50 mL/min (n = 1480, 22%). In the normal renal function group, 1609 (30%) received 10 mg/day (under-dose), while in the renal dysfunction group, 108 (7%) received 15 mg/day (over-dose). In the normal renal function group, under-dose of rivaroxaban was associated with higher all-cause mortality, while in the renal dysfunction group, over-dose was associated with higher incidence of major bleeding. In contrast, the incidence of stroke or systemic embolism was not different between the 2 groups regardless of the dose of rivaroxaban. In the propensity score matched analysis to adjust the difference in characteristics according to doses of rivaroxaban, the incidences of clinical outcomes were comparable between the 2 dose groups in both renal function groups. These results indicate that the dose of rivaroxaban should be reduced depending on the renal function, considering the balance between risks of bleeding and ischemia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey.
- Author
-
Shimamura, Munehisa, Kaikita, Koichi, Nakagami, Hironori, Kawano, Tomohiro, Ju, Nan, Hayashi, Hiroki, Nakamaru, Ryo, Yoshida, Shota, Sasaki, Tsutomu, Mochizuki, Hideki, Tsujita, Kenichi, and Morishita, Ryuichi
- Subjects
STROKE ,CALCIUM-binding proteins ,PLATELET aggregation inhibitors ,PATIENT compliance ,LABORATORY monkeys - Abstract
In post-stroke patients, a decreased adherence to antiplatelet drugs is a major challenge in the prevention of recurrent stroke. Previously, we reported an antiplatelet vaccine against S100A9 in mice, but the use of Freund's adjuvant and the difference in amino acid sequences in epitopes between mice and humans were problematic for clinical use. Here, we redesigned the S100A9 vaccine for the common sequence in both humans and monkeys and examined its effects in cynomolgus monkeys with Alum adjuvant. First, we assessed several candidate epitopes and selected 102 to 112 amino acids as the suitable epitope, which could produce antibodies. When this peptide vaccine was intradermally injected into 4 cynomolgus monkeys with Alum, the antibody against human S100A9 was successfully produced. Anti-thrombotic effects were shown in two monkeys in a mixture of vaccinated serum and fresh whole blood from another cynomolgus monkey. Additionally, the anti-thrombotic effects were partially inhibited by the epitope peptide, indicating the feasibility of neutralizing anti-thrombotic effects of produced antibodies. Prolongation of bleeding time was not observed in vaccinated monkeys. Although further studies on increasing the effect of vaccine and safety are necessary, this vaccine will be a promising approach to improve adherence to antiplatelet drugs in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Comparison of electron microscopic findings and clinical presentation in three patients with mitochondrial cardiomyopathy caused by the mitochondrial DNA mutation m.3243A > G.
- Author
-
Saku, Taiki, Takashio, Seiji, Tsuruta, Yuichiro, Otsuka, Yasuhiro, Takae, Masafumi, Kiyama, Takuya, Yamamoto, Eichiro, Kaikita, Koichi, Hotta, Taeko, Matsumoto, Shinya, Kang, Dongchon, Tsujita, Kenichi, and Komohara, Yoshihiro
- Subjects
MITOCHONDRIAL DNA ,MITOCHONDRIA ,HEART failure ,CARDIOMYOPATHIES ,NUCLEAR DNA ,CARDIAC hypertrophy - Abstract
Mitochondrial cardiomyopathy can be described as a condition characterized by abnormal heart-muscle structure and/or function, secondary to mutations in nuclear or mitochondrial DNA. Its severity can range from subclinical to critical conditions. We presented three cases of mitochondrial cardiomyopathy with m.3243A > G mutation and compared the clinical manifestations with the histological findings for each of these cases. All cases showed cardiac hypertrophy, juvenile-onset diabetes mellitus, and hearing loss. Case 1 (43-year-old male) showed less cardiac involvement and shorter duration of mitochondrial disease-related symptoms than case 2 (67-year-old female) and case 3 (51-year-old male), who showed the most advanced cardiac condition and longest duration from the manifestation of heart failure. The histological findings revealed that cardiomyocytes from case 1 showed no hypertrophy and mitochondrial degeneration in electron microscopy. Alternatively, cases 2 and 3 showed hypertrophy in their cardiomyocytes, and mitochondrial degeneration (e.g. onion-like lesions, swollen cristae, and lamellar bodies) was most apparent in case 3. These results suggested that mitochondrial degeneration, as evaluated by electron microscopy, might be correlated with impaired heart function in patients with mitochondrial cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease.
- Author
-
Suzuki, Satoru, Kaikita, Koichi, Yamamoto, Eiichiro, Jinnouchi, Hideaki, and Tsujita, Kenichi
- Abstract
Coronary angiography (CAG) sometimes shows nonobstructive coronary arteries in patients with suspected angina or acute coronary syndrome (ACS). The high prevalence of nonobstructive coronary artery disease (CAD) in those patients has recently been reported not only in Japan but also in Western countries, and is clinically attracting attention. Coronary spasm is considered to be one of the leading causes of both suspected stable angina and ACS with nonobstructive coronary arteries. Coronary spasm could also be associated with left ventricular dysfunction leading to heart failure, which could be improved following the administration of calcium channel blockers. Because we rarely capture spontaneous attacks of coronary spasm with electrocardiograms or Holter recordings, an invasive diagnostic modality, acetylcholine (ACh) provocation test, can be useful in detecting coronary spasm during CAG. Furthermore, we can use the ACh-provocation test to identify high-risk patients with coronary spasm complicated with organic coronary stenosis, and then treat with intensive care. Nonobstructive CAD includes not only epicardial coronary spasm but also microvascular spasm or dysfunction that can be associated with recurrent anginal attacks and poor quality of life. ACh-provocation test could also be helpful for the assessment of microvascular spasm or dysfunction. We hope that cardiologists will increasingly perform ACh-provocation test to assess the pathophysiology of nonobstructive CAD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Similarity and simultaneity of triphasic mitral inflow and pulmonary venous flow in a patient with broad apical aneurysm.
- Author
-
Misumi, Ikuo, Sato, Koji, Nagano, Miwa, Korogi, Wataru, Usuku, Hiroki, Kaikita, Koichi, and Tsujita, Kenichi
- Published
- 2022
- Full Text
- View/download PDF
22. Usefulness of relative apical longitudinal strain index to predict positive 99mTc‐labeled pyrophosphate scintigraphy findings in advanced‐age patients with suspected transthyretin amyloid cardiomyopathy.
- Author
-
Usuku, Hiroki, Takashio, Seiji, Yamamoto, Eiichiro, Kinoshita, Yui, Nishi, Masato, Oike, Fumi, Marume, Kyohei, Hirakawa, Kyoko, Tabata, Noriaki, Oda, Seitaro, Misumi, Yohei, Ueda, Mitsuharu, Kawano, Hiroaki, Kaikita, Koichi, Matsushita, Kenichi, Ando, Yukio, Matsui, Hirotaka, and Tsujita, Kenichi
- Subjects
PERIPHERAL neuropathy diagnosis ,AMYLOID ,AMYLOIDOSIS ,CONFIDENCE intervals ,ECHOCARDIOGRAPHY ,MULTIVARIATE analysis ,CARDIOMYOPATHIES ,SERUM albumin ,LOGISTIC regression analysis ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio ,OLD age - Abstract
Background: We previously reported that a high score (2 or 3 points) according to the Kumamoto criteria, a combination of high‐sensitivity cardiac troponin T (hs‐cTnT) ≥0.308 ng/mL, the length of QRS ≥ 120 ms in electrocardiogram, and left ventricular (LV) posterior wall thickness ≥ 13.6 mm, increases the pretest probability of 99mTc‐labeled pyrophosphate (99mTc‐PYP) scintigraphy in patients with suspected transthyretin amyloid cardiomyopathy (ATTR‐CM). However, some patients with a low score (0 or 1 point) show positive findings on 99mTc‐PYP scintigraphy. Therefore, we evaluated the usefulness of additional examinations, including echocardiographic assessment of myocardial strain, to raise the pretest probability of 99mTc‐PYP scintigraphy for these patients. Methods and Results: We examined 109 consecutive patients aged ≥70 years with low scores according to the Kumamoto criteria who underwent 99mTc‐PYP scintigraphy. Nineteen patients (17%) had positive 99mTc‐PYP scintigraphy findings. The relative apical longitudinal strain (LS) index (apical LS/ basal LS + mid LS) (RapLSI) was significantly higher in patients with positive than negative 99mTc‐PYP scintigraphy findings (1.04 ± 0.37 vs 0.70 ± 0.28, P <.01). Multivariable logistic regression analysis revealed that a high RapLSI (≥1.04) was significantly associated with 99mTc‐PYP positivity (odds ratio, 14.14; 95% confidence interval, 3.36‐59.47; P <.01). The sensitivity, specificity, and accuracy of the diagnostic model using the RapLSI for identification of 99mTc‐PYP positivity were 53%, 94%, and 87%, respectively. Conclusions: A high RapLSI can raise the pretest probability of 99mTc‐PYP scintigraphy in patients with a low score according to the Kumamoto criteria. The RapLSI can assist clinicians in determining strategies for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Association of short term exposure to Asian dust with increased blood pressure.
- Author
-
Ishii, Masanobu, Seki, Tomotsugu, Sakamoto, Kenji, Kaikita, Koichi, Miyamoto, Yoshihiro, Tsujita, Kenichi, Masuda, Izuru, and Kawakami, Koji
- Subjects
BLOOD pressure ,AIR pollution ,ASTHMA ,HUMIDITY ,HYPERTENSION - Abstract
Air pollution causes hypertension, cardiovascular disease, and mortality. Asian dust (AD) reportedly induces asthma or acute myocardial infarction along with air pollution, but its impact on blood pressure (BP) is unknown. We investigated the association between short-term AD exposure and BP fluctuations in 300,952 individuals whose BP was measured during April 2005–March 2015 and divided them into AD and non-AD groups based on visitation for AD-related events. AD's occurrence, air pollutants' concentration (suspended particulate matter, SO
2 , NO2 , photochemical oxidants), and meteorological variables (mean ambient temperature, relative humidity) were obtained from a monitoring station; AD events correlated with decreased visibility (< 10 km). We observed 61 AD days, with 3897 participants undergoing medical check-ups. Short-term AD exposure at lag day-0 was significantly associated with higher systolic BP (SBP), diastolic BP (DBP), and pulse rate (PR) risk (β = 1.85, 95% confidence interval (CI) 1.35–2.35 for SBP, β = 2.24, 95% CI 1.88–2.61 for DBP, β = 0.52, 95% CI 0.14–0.91 for PR) using multi-pollutant model. Population-attributable fractions exposed to AD were 11.5% for those with elevated SBP (SBP ≥ 120 mmHg) and 23.7% for those with hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg). This study showed a strong association between short-term AD exposure and increased SBP and DBP. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan.
- Author
-
Yamada, Toshihiro, Takashio, Seiji, Arima, Yuichiro, Nishi, Masato, Morioka, Mami, Hirakawa, Kyoko, Hanatani, Shinsuke, Fujisue, Koichiro, Yamanaga, Kenshi, Kanazawa, Hisanori, Sueta, Daisuke, Araki, Satoshi, Usuku, Hiroki, Nakamura, Taishi, Suzuki, Satoru, Yamamoto, Eiichiro, Ueda, Mitsuharu, Kaikita, Koichi, and Tsujita, Kenichi
- Subjects
CARDIAC amyloidosis ,TRANSTHYRETIN ,HEART failure - Abstract
Aims: The focus on wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is increasing because of novel treatment options. There is currently no report on a large number of Japanese patients with ATTRwt‐CM. The study aimed to examine the characteristics and prognosis of ATTRwt‐CM in Japan. Methods and results: Consecutive patients (78.5 ± 6.4 years old at diagnosis) with ATTRwt‐CM diagnosed at Kumamoto University Hospital between December 2002 and December 2019 were retrospectively reviewed. Data, including demographic characteristics, co‐morbidities, clinical manifestations at diagnosis, laboratory results, electrocardiographic and echocardiographic data, imaging and pathological findings, and treatment were obtained. Of 129 patients included in this study, 110 patients (85%) were male. The median period from initial symptom onset to diagnosis was 15.5 (2–75) months. Heart failure was the most common clinical manifestation leading to diagnosis (61%) and initial manifestations (49%). Of 106 patients, carpal tunnel syndrome was observed in 57 patients (54%), and the median period from initial symptom onset to diagnosis was 96 (48–120) months. Histopathological confirmation of transthyretin amyloid was achieved in 94 patients (73%), including 66 (51%) and 28 cases (22%) with endomyocardial and extracardiac biopsies. During the observation period (median 15.0 [inter‐quartile range, 5.4–33.2] months after diagnosis), 34 patients (26%) died. Of these, 27 patients (79%) had cardiovascular deaths (heart failure, 25; sudden death, two). The median survival duration was 58.9 months and the 5 years' survival rate was 48%. According to a multivariate Cox hazard analysis, age [hazard ratio (HR), 1.14; 95% confidence interval (CI), 1.05–1.23, P = 0.002] and low serum sodium levels (HR, 0.89; 95% CI, 0.79–0.996; P = 0.04) contributed to all‐cause mortality, and low serum sodium levels contributed to hospitalization for heart failure (HR, 0.86; 95% CI, 0.77–0.96; P = 0.005). Conclusions: Clinical characteristics and prognosis of ATTRwt‐CM patients in Japan were examined. Carpal tunnel syndrome can be considered an indication for diagnosis of ATTRwt‐CM. Age and low serum sodium level were significant predictive factors of all survival outcomes. The clinical features of ATTRwt‐CM should be recognized to provide appropriate treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus‐formation analysis system.
- Author
-
Takashio, Seiji, Kaikita, Koichi, Nishi, Masato, Morioka, Mami, Higo, Taiki, Shiose, Akira, Doman, Tsuyoshi, Horiuchi, Hisanori, Fukui, Toshihiro, and Tsujita, Kenichi
- Subjects
VON Willebrand disease ,HEART assist devices ,HEMORRHAGE - Abstract
Aims: Bleeding is a serious complication in patients with continuous‐flow left ventricular assist device (CF‐LVAD). Acquired von Willebrand syndrome (AVWS; type 2A) develops because of high shear stress inside the pumps and is a cause of bleeding complication. Although von Willebrand factor (vWF) multimer analysis is useful for diagnosing AVWS, it is only performed in specialized research institutes. A novel microchip flow chamber system, the total thrombus‐formation analysis system (T‐TAS), is a point‐of‐care system to evaluate the thrombus‐formation process and useful for monitoring platelet thrombus‐formation capacity in patients receiving antiplatelet therapy and the diagnosis and evaluation of the clinical severity of von Willebrand disease type 1. However, little is known about the association between AVWS and platelet thrombus‐formation capacity evaluated by T‐TAS in patients with CF‐LVAD. We aimed to evaluate the utility of T‐TAS for easy detection of AVWS in patients with CF‐LVAD. Methods and results: We simultaneously evaluated the vWF large multimers and T‐TAS parameters in four consecutive patients with axial‐type CF‐LVAD and eight control patients treated with aspirin and warfarin. vWF large multimer index was defined as the proportion of large multimers in total vWF derived from a normal control plasma. T‐TAS analyses different thrombus‐formation processes using two microchips with different thrombogenic surfaces. PL24‐AUC10 levels in the platelet (PL) chip are highly sensitive for platelet functions, while AR10‐AUC30 levels in the atheroma (AR) chip allow the assessment of the overall haemostatic ability. vWF large multimer index and T‐TAS parameters were decreased in all patients with CF‐LVAD. The mean PL24‐AUC10 level (5.4 ± 2.9 vs. 219 ± 67; P < 0.01), AR10‐AUC30 level (338 ± 460 vs. 1604 ± 160; P < 0.01) and vWF large multimer index (49 ± 11% vs. 112 ± 27%; P < 0.01) were significantly lower in the patients with CF‐LVAD than in control patients. One patient showed changes in T‐TAS levels before and after implantation of CF‐LVAD. PL24‐AUC10 and AR10‐AUC30 levels decreased from 438.1 to 5.0 and from 1667.9 to 1134.3, respectively. Conclusions: In patients with CF‐LVAD, the platelet thrombus‐formation capacity was extremely impaired because of AVWS, and T‐TAS parameters could detect the presence of AVWS. T‐TAS can be used for easy detection of AVWS as a point‐of‐care testing. Further studies with a large sample size are needed to validate our results in several LVAD models and evaluate the prognostic value of bleeding complications and thromboembolism in patients with LVAD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Left‐dominant arrhythmogenic cardiomyopathy with a nonsense mutation in DSP.
- Author
-
Tsuruta, Yuichiro, Sueta, Daisuke, Takashio, Seiji, Oda, Seitaro, Sakamoto, Kenij, Kaikita, Koichi, Kato, Koichi, Ohno, Seiko, Horie, Minoru, and Tsujita, Kenichi
- Subjects
VENTRICULAR tachycardia ,ELECTROCARDIOGRAPHY - Abstract
A 74‐year‐old man had abnormal left ventricular (LV) function according to a perioperative test at a local hospital and was transferred to our institution for further evaluation and treatment. His electrocardiogram demonstrated the presence of premature ventricular contraction with a QRS complex of the right bundle branch block type and superior axis. His echocardiography showed systolic dysfunction of the LV (LV ejection fraction, 44.6%). Cardiac computed tomography imaging revealed banded and patchy densities observed frequently from the middle to epicardial layer of the LV wall. Cardiac magnetic resonance imaging showed fat signals on fat‐selective images and late gadolinium enhancement in the mid‐wall to subepicardial layers in the LV myocardium. Endomyocardial biopsy revealed the histological presence of fibrofatty replacement. A genetic analysis revealed a nonsense mutation in the desmoplakin gene. Thus, he was diagnosed with left‐dominant arrhythmogenic cardiomyopathy. To prevent fatal ventricular arrhythmias, an implantable cardioverter defibrillator was successfully implanted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Hypertrophic obstructive cardiomyopathy with left ventricular outflow and mid obstruction with apical aneurysm: a case report.
- Author
-
Misumi, Ikuo, Sato, Koji, Nagano, Miwa, Yamada, Yuriko, Urata, Joji, Kaikita, Koichi, and Tsujita, Kenichi
- Published
- 2021
- Full Text
- View/download PDF
28. Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
- Author
-
Yoshiyuki Yazaki, Masato Nakamura, Raisuke Iijima, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Yazaki, Yoshiyuki, Nakamura, Masato, Iijima, Raisuke, Yasuda, Satoshi, Kaikita, Koichi, and Akao, Masaharu
- Published
- 2021
- Full Text
- View/download PDF
29. Short-term exposure to desert dust and the risk of acute myocardial infarction in Japan: a time-stratified case-crossover study.
- Author
-
Ishii, Masanobu, Seki, Tomotsugu, Kaikita, Koichi, Sakamoto, Kenji, Nakai, Michikazu, Sumita, Yoko, Nishimura, Kunihiro, Miyamoto, Yoshihiro, Noguchi, Teruo, Yasuda, Satoshi, Tsutsui, Hiroyuki, Komuro, Issei, Saito, Yoshihiko, Ogawa, Hisao, Tsujita, Kenichi, and Kawakami, Koji
- Subjects
MYOCARDIAL infarction ,DUST ,CORONARY disease ,PARTICULATE matter ,CORONARY arteries ,LOGISTIC regression analysis - Abstract
Particulate matter from natural sources such as desert dust causes harmful effects for health. Asian dust (AD) increases the risk of acute myocardial infarction (AMI). However, little is known about the risk of myocardial infarction with nonobstructive coronary arteries (MINOCA), compared to myocardial infarction with coronary artery disease (MI-CAD). Using a time-stratified case-crossover design and conditional logistic regression models, the association between short-term exposure to AD whereby decreased visibility (< 10 km) observed at each monitoring station nearest to the hospitals was used for exposure measurements and admission for AMI in the spring was investigated using a nationwide administrative database between April 2012 and March 2016. According to presence of revascularization and coronary atherosclerosis, AMI patients (n = 30,435) were divided into 2 subtypes: MI-CAD (n = 27,202) or MINOCA (n = 3233). The single lag day-2 was used in AD exposure based on the lag effect analysis. The average level of meteorological variables and co-pollutants on the 3 days prior to the case/control days were used as covariates. The occurrence of AD events 2 days before the admission was associated with admission for MINOCA after adjustment for meteorological variables [odds ratio 1.65; 95% confidence interval (CI) 1.18–2.29], while the association was not observed in MI-CAD. The absolute risk difference of MINOCA admission was 1.79 (95% CI 1.21–2.38) per 100,000 person-year. These associations between AD exposure and the admission for MINOCA remained unchanged in two-pollutant models. This study provides evidence that short-term exposure to AD is associated with a higher risk of MINOCA, but not MI-CAD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture.
- Author
-
Sueta, Daisuke, Tabata, Noriaki, Tanaka, Motoko, Hanatani, Shinsuke, Arima, Yuichiro, Sakamoto, Kenji, Yamamoto, Eiichiro, Izumiya, Yasuhiro, Kaikita, Koichi, Arizono, Kenji, Matsui, Kunihiko, and Tsujita, Kenichi
- Subjects
HEMODIALYSIS patients ,CALCIUM phosphate ,CALCIUM ,SERUM ,PHOSPHORUS - Abstract
Introduction: Mortality in hemodialysis patients is relatively high; thus, its risk stratification is very important. There are insufficient data describing the current status of the management of serum phosphate and calcium levels. Methods: We conducted a multicenter, prospective, registry study throughout the Kumamoto Prefecture in Japan. We enrolled 1993 patients at 58 facilities with complete explanatory data, including serum phosphate, corrected calcium, and intact parathyroid hormone levels. We categorized subjects into nine categories according to low, normal, and high levels of phosphate and corrected calcium levels. The endpoint was all‐cause mortality. Results: Of the total number of subjects, 56.1% of the patients were in the normal phosphate and calcium category, and 72% and 77.1% had controlled serum phosphate and calcium levels, respectively. Two hundred twenty‐six deaths occurred during the follow‐up period. In the nine categories, the highest mortality rates were observed in the highest corrected calcium and lowest phosphate categories. Stepwise backward multivariate regression analyses identified the serum corrected calcium level (OR, 1.38; 95% CI, 1.06–1.79; P = 0.016) and the serum phosphate level (OR, 1.26; 95% CI, 1.08–1.48; P = 0.003) as significant and independent predictors of all‐cause mortality. Conclusions: The corrected serum calcium and phosphate levels are associated with mortality in our dialysis population, with poorest survival in patients with high corrected serum calcium and low serum phosphorus. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture.
- Author
-
Sueta, Daisuke, Tabata, Noriaki, Tanaka, Motoko, Hanatani, Shinsuke, Arima, Yuichiro, Sakamoto, Kenji, Yamamoto, Eiichiro, Izumiya, Yasuhiro, Kaikita, Koichi, Arizono, Kenji, Matsui, Kunihiko, and Tsujita, Kenichi
- Published
- 2020
- Full Text
- View/download PDF
32. Double‐chambered right ventricle complicated by hypertrophic obstructive cardiomyopathy diagnosed as Noonan syndrome.
- Author
-
Yamamoto, Masahiro, Takashio, Seiji, Nakashima, Naoya, Hanatani, Shinsuke, Arima, Yuichiro, Sakamoto, Kenji, Yamamoto, Eiichiro, Kaikita, Koichi, Aoki, Yoko, and Tsujita, Kenichi
- Subjects
CONGENITAL heart disease ,CARDIOMYOPATHIES ,NOONAN syndrome - Abstract
We present a case of double‐chambered right ventricle (DCRV) complicated by hypertrophic obstructive cardiomyopathy (HOCM) in KRAS mutation‐associated Noonan syndrome. The diagnosis was incidental and made during diagnostic testing for an intradural extramedullary tumour. Spinal compression, if not surgically treated, may cause paralysis of the extremities. We decided to pursue pharmacological therapy to control biventricular obstructions and reduce the perioperative complication rate. We initiated treatment with cibenzoline and bisoprolol; the doses were titrated according to the response. After 2 weeks, the peak pressure gradient of the two RV chambers decreased from 101 to 68 mmHg, and the LV peak pressure gradient decreased from 109 to 14 mmHg. Class 1A antiarrhythmic drugs and β‐blockers decreased the severe pressure gradients of biventricular obstructions caused by DCRV and HOCM. The patient was able to undergo surgery to remove the intradural extramedullary tumour, which was diagnosed as schwannoma. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Myocardial extracellular volume quantification in cardiac CT: comparison of the effects of two different iterative reconstruction algorithms with MRI as a reference standard.
- Author
-
Emoto, Takafumi, Kidoh, Masafumi, Oda, Seitaro, Nakaura, Takeshi, Nagayama, Yasunori, Sasao, Akira, Funama, Yoshinori, Araki, Satoshi, Takashio, Seiji, Sakamoto, Kenji, Yamamoto, Eiichiro, Kaikita, Koichi, Tsujita, Kenichi, and Yamashita, Yasuyuki
- Subjects
IMAGE analysis ,STATISTICAL correlation - Abstract
Objectives: To compare the effects of hybrid iterative reconstruction (HIR) and model-based iterative reconstruction (MBIR) that incorporates a beam-hardening model for myocardial extracellular volume (ECV) quantification by cardiac CT using MRI as a reference standard.Methods: In this retrospective study, a total of 34 patients were evaluated using cardiac CT and MRI. Paired CT image sets were created using HIR and MBIR with a beam-hardening model. We calculated mean absolute differences and correlations between the global mid-ventricular ECV derived from CT and MRI via Pearson correlation analysis. In addition, we performed qualitative analysis of image noise and beam-hardening artifacts on postcontrast images using a four-point scale: 1 = extensive, 2 = strong, 3 = mild, and 4 = minimal.Results: The mean absolute difference between the ECV derived from CT and MRI for MBIR was significantly smaller than that for HIR (MBIR 3.74 ± 3.59%; HIR 4.95 ± 3.48%, p = 0.034). MBIR improved the correlation between the ECV derived from CT and MRI when compared with HIR (MBIR, r = 0.60, p < 0.001; HIR, r = 0.47, p = 0.006). In qualitative analysis, MBIR significantly reduced image noise and beam-hardening artifacts when compared with HIR ([image noise, MBIR 3.4 ± 0.7; HIR 2.1 ± 0.8, p < 0.001], [beam-hardening artifacts, MBIR 3.8 ± 0.4; HIR 2.6 ± 1.0, p < 0.001]).Conclusions: MBIR with a beam-hardening model effectively reduced image noise and beam-hardening artifacts and improved myocardial ECV quantification when compared with HIR using MRI as a reference standard.Key Points: • MBIR with a beam-hardening model effectively reduced image noise and beam-hardening artifacts. • The mean absolute difference between the global mid-ventricular ECV derived from CT and MRI for MBIR was significantly smaller than that for conventional HIR. • MBIR provided more accurate myocardial CT number and improved ECV quantification when compared with HIR. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
34. H2FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors.
- Author
-
Suzuki, Satoru, Kaikita, Koichi, Yamamoto, Eiichiro, Sueta, Daisuke, Yamamoto, Masahiro, Ishii, Masanobu, Ito, Miwa, Fujisue, Koichiro, Kanazawa, Hisanori, Araki, Satoshi, Arima, Yuichiro, Takashio, Seiji, Usuku, Hiroki, Nakamura, Taishi, Sakamoto, Kenji, Izumiya, Yasuhiro, Soejima, Hirofumi, Kawano, Hiroaki, Jinnouchi, Hideaki, and Matsui, Kunihiko
- Subjects
PROGNOSIS ,HEART failure ,VENTRICULAR ejection fraction ,DYSPNEA ,OUTPATIENT medical care ,ECHOCARDIOGRAPHY - Abstract
Aims: The prediction of future heart failure (HF) in stable outpatients is often difficult for general practitioners and cardiologists. Recently, the H2FPEF score (0–9 points) has been proposed for the discrimination of HF with preserved ejection fraction from non‐cardiac causes of dyspnoea. The six clinical and echocardiographic variables that constitute the H2FPEF score include the following: (i) obesity (H); (ii) the use of ≥2 antihypertensive drugs (H); (iii) atrial fibrillation (F); (iv) pulmonary hypertension (P); (v) an age > 60 years (E); and (vi) E/e' > 9 (F). We performed an external validation study that investigated whether the H2FPEF score could predict future HF‐related events in stable outpatients with cardiovascular risk factor(s) in Japan. Methods and results: In this prospective cohort study, after exclusion of 195 from 551 consecutive, stable Japanese outpatients with at least one cardiovascular risk factor who were enrolled between September 2010 and July 2013, the remaining 356 outpatients (171 men, 185 women, mean age 73.2 years) were eligible for the analysis. We calculated the H2FPEF score (0–9 points), and followed up the patients for an average of 517 days. In all of the 356 patients, the mean H2FPEF score was 3.1 ± 1.8, and 15 developed HF‐related events during the follow‐up period, including cardiovascular death (n = 2) and hospitalization for HF decompensation (n = 13). Multivariate Cox proportional hazards analysis showed that the H2FPEF score was an independent predictor of future HF‐related events (P < 0.001 for all three models). Kaplan–Meier survival curves showed a significantly higher probability of HF‐related events in the outpatients with a high H2FPEF score (P < 0.001). In receiver operating characteristic (ROC) curve analysis, the H2FPEF score was significantly associated with the occurrence of future HF‐related events (P < 0.001). In ROC curve analysis, the sensitivity, specificity, and positive likelihood ratio of a H2FPEF score of 7 points to predict HF‐related events were 47%, 96%, and 11.4%, respectively. Conclusions: The H2FPEF score could provide useful information for future HF‐related events in stable outpatients with cardiovascular risk factor(s) in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Cardiomyocyte Sirt (Sirtuin) 7 Ameliorates Stress-Induced Cardiac Hypertrophy by Interacting With and Deacetylating GATA4.
- Author
-
Yamamura, Satoru, Izumiya, Yasuhiro, Araki, Satoshi, Nakamura, Taishi, Kimura, Yuichi, Hanatani, Shinsuke, Yamada, Toshihiro, Ishida, Toshifumi, Yamamoto, Masahiro, Onoue, Yoshiro, Arima, Yuichiro, Yamamoto, Eiichiro, Sunagawa, Yoichi, Yoshizawa, Tatsuya, Nakagata, Naomi, Bober, Eva, Braun, Thomas, Sakamoto, Kenji, Kaikita, Koichi, and Morimoto, Tatsuya
- Published
- 2020
- Full Text
- View/download PDF
36. H2FPEF Score as a Prognostic Value in HFpEF Patients.
- Author
-
Sueta, Daisuke, Yamamoto, Eiichiro, Nishihara, Taiki, Tokitsu, Takanori, Fujisue, Koichiro, Oike, Fumi, Takae, Masafumi, Usuku, Hiroki, Takashio, Seiji, Arima, Yuichiro, Suzuki, Satoru, Nakamura, Taishi, Ito, Miwa, Kanazawa, Hisanori, Sakamoto, Kenji, Kaikita, Koichi, and Tsujita, Kenichi
- Subjects
ANGINA pectoris ,RECEIVER operating characteristic curves ,VENTRICULAR ejection fraction ,CARDIOVASCULAR diseases ,LOG-rank test - Abstract
Background The H
2 FPEF score is recognized as a simple method to diagnose heart failure (HF) with preserved left ventricular ejection fraction (HFpEF). We investigated the value of the H2 FPEF score in predicting subsequent cardiovascular events in HFpEF patients. Methods This study was a retrospective, single-center, observational study. We calculated the H2 FPEF scores for 404 consecutive HFpEF patients. Subjects were subdivided into low- (0–3), intermediate- (4–6), and high-score (7–9) groups and followed for 50 months. The primary and secondary endpoints were composite cardiovascular/cerebrovascular events (cardiovascular death, nonfatal myocardial infarction, unstable angina pectoris, hospitalization for HF decompensation, and nonfatal stroke) occurrence and HF-related events (hospitalization for HF decompensation) occurrence at 50 months, respectively. Results Kaplan–Meier analyses demonstrated a significantly higher incidence of cardiovascular/cerebrovascular events among those with a higher H2 FPEF score (log-rank test, P = 0.005). The HF-related event rate was higher in proportion to the H2 FPEF score (log-rank test, P < 0.001). Multivariate Cox hazard analyses identified the H2 FPEF score (per 1 point) as an independent predictor of cardiovascular and HF-related events (hazard ratio [HR], 1.179; 95% confidence interval [CI], 1.066–1.305; P = 0.001 and HR, 1.288; 95% CI, 1.134–1.463; P = 0.001, respectively). Receiver operating characteristic analysis showed that the H2 FPEF significantly predicted cardiovascular events (area under the curve [AUC], 0.626; 95% CI, 0.557–0.693; P < 0.001) and HF-related events (AUC, 0.680; 95% CI, 0.600–0.759; P < 0.001). The cutoff H2 FPEF score was 5.5 for the identification of cardiovascular and HF-related events. Conclusion The H2 FPEF score might be a potentially useful marker for the prediction of cardiovascular and HF-related events in HFpEF patients. Clinical Trails Registration Trail Number UMIN000029600. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
37. Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
- Author
-
Sakuma, Ichiro, Uchiyama, Shinichiro, Atarashi, Hirotsugu, Inoue, Hiroshi, Kitazono, Takanari, Yamashita, Takeshi, Shimizu, Wataru, Ikeda, Takanori, Kamouchi, Masahiro, Kaikita, Koichi, Fukuda, Koji, Origasa, Hideki, and Shimokawa, Hiroaki
- Subjects
ATRIAL fibrillation ,DISEASE risk factors ,HEMORRHAGE ,STROKE - Abstract
In the original publication of the article, the Figure 2b and the Tables 2 and 3 were published incorrectly. The corrected figure and tables are provided below. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
- Author
-
Sakuma, Ichiro, Uchiyama, Shinichiro, Atarashi, Hirotsugu, Inoue, Hiroshi, Kitazono, Takanari, Yamashita, Takeshi, Shimizu, Wataru, Ikeda, Takanori, Kamouchi, Masahiro, Kaikita, Koichi, Fukuda, Koji, Origasa, Hideki, and Shimokawa, Hiroaki
- Subjects
ATRIAL fibrillation ,RECEIVER operating characteristic curves ,DISEASE risk factors ,PROPORTIONAL hazards models ,HEMORRHAGE - Abstract
For Japanese patients with non-valvular atrial fibrillation (NVAF), the risk of stroke and major bleeding events was assessed by using the CHADS
2, CHA2 DS2 -VASc, and HAS-BLED scores. The risk factors for embolism and major bleeding under DOAC may be different from current reports. We analyzed the data set of the EXPAND Study to determine the risk factors for events among Japanese NVAF patients in the era of direct oral anticoagulant. Using the data of EXPAND Study, the validity for predictability of the CHADS2 , CHA2 DS2 -VASc, and HAS-BLED scores was identified using the receiver operating characteristic curve analysis. Multivariate analysis was performed with the Cox proportional hazard model to determine the independent risk factors for stroke/systemic embolism and major bleeding among NVAF patients receiving rivaroxaban. Explanatory variables were selected based on the univariate analysis. A total of 7141 patients (mean age 71.6 ± 9.4 years, women 32.3%, and rivaroxaban 15 mg per day 56.5%) were included. Incidence rates of stroke/systemic embolism and major bleeding were 1.0%/year and 1.2%/year, respectively. The multivariate analysis revealed that only history of stroke was associated with stroke/systemic embolism (hazard ratio 3.4, 95% confidence interval 2.5-4.7, p < 0.0001). By contrast, age (1.7, 1.1–2.6, p = 0.0263), creatinine clearance (CrCl) 30–49 mL/min (1.6, 1.2-2.2, p = 0.0011), liver dysfunction (1.7, 1.1–2.8, p = 0.0320), history/disposition of bleeding (1.8, 1.0–3.0, p = 0.0348), and concomitant use of antiplatelet agents (1.6, 1.2–2.3, p = 0.0030) were associated with major bleeding. This sub-analysis showed that some components of the HAS-BLED score were independently associated with major bleeding in Japanese NVAF patients receiving anticoagulation therapy by rivaroxaban. Additionally, CrCl value of 30–49 mL/min was an independent predictor of major bleeding in patients receiving rivaroxaban. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
39. Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease.
- Author
-
Kaikita, Koichi, Hosokawa, Kazuya, Dahlen, Jeffrey R., and Tsujita, Kenichi
- Published
- 2019
- Full Text
- View/download PDF
40. Clinical Significance of Brachial-Ankle Pulse Wave Velocity in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction.
- Author
-
Takae, Masafumi, Yamamoto, Eiichiro, Tokitsu, Takanori, Oike, Fumi, Nishihara, Taiki, Fujisue, Koichiro, Sueta, Daisuke, Usuku, Hiroki, Motozato, Kota, Ito, Miwa, Kanazawa, Hisanori, Araki, Satoshi, Nakamura, Taishi, Arima, Yuichiro, Takashio, Seiji, Suzuki, Satoru, Sakamoto, Kenji, Soejima, Hirofumi, Yamabe, Hiroshige, and Kaikita, Koichi
- Subjects
HEART failure ,VENTRICULAR ejection fraction ,HEART failure patients ,ANGIOTENSIN converting enzyme - Abstract
The article offers information on the clinical significance of brachial-ankle pulse wave velocity in patients with heart failure With Reduced Left Ventricular ejection fraction. Topics discussed include measurement of ankle-brachial pressure index (ABI) and baPWV values at stable condition after optimal therapy for HF in 201 consecutive HFrEF patients; and concludes that identifying complications of Peripheral arterial disease and measuring baPWV values in HFrEF patients were useful.
- Published
- 2019
- Full Text
- View/download PDF
41. A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention.
- Author
-
Tabata, Noriaki, Sueta, Daisuke, Yamamoto, Eiichiro, Takashio, Seiji, Arima, Yuichiro, Araki, Satoshi, Yamanaga, Kenshi, Ishii, Masanobu, Sakamoto, Kenji, Kanazawa, Hisanori, Fujisue, Koichiro, Hanatani, Shinsuke, Soejima, Hirofumi, Hokimoto, Seiji, Izumiya, Yasuhiro, Kojima, Sunao, Yamabe, Hiroshige, Kaikita, Koichi, Matsui, Kunihiko, and Tsujita, Kenichi
- Published
- 2019
- Full Text
- View/download PDF
42. Subdivision of the left ventricle by a discrete ridge and anomalous papillary muscle causing mid‐ventricular obstruction: A case report.
- Author
-
Misumi, Ikuo, Motozato, Kota, Yamabe, Hiroshige, Ohmori, Kunihiro, Usuku, Hiroki, Kaikita, Koichi, and Tsujita, Kenichi
- Subjects
CARDIAC hypertrophy ,VENTRICULAR outflow obstruction ,DOPPLER echocardiography ,ELECTROCARDIOGRAPHY ,LEFT heart ventricle ,HEART conduction system ,HEART murmurs ,PATIENT aftercare ,MYOCARDIUM ,DIAGNOSIS - Abstract
A 16‐year‐old healthy boy visited our department because of a heart murmur. A 12‐lead electrocardiogram showed left QRS axis deviation and repolarization abnormalities. Transthoracic echocardiography and a computed tomographic scan revealed a hypertrophied papillary muscle and a discrete ridge arising from the septal wall, causing mid‐ventricular obstruction. Doppler echocardiography revealed that the pressure gradient at the obstruction was mild. The patient will be followed up annually, without medication or physical restriction. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Comprehensive assessment of takotsubo cardiomyopathy by cardiac computed tomography.
- Author
-
Sueta, Daisuke, Oda, Seitaro, Izumiya, Yasuhiro, Kaikita, Koichi, Kidoh, Masafumi, Utsunomiya, Daisuke, Yamashita, Yasuyuki, and Tsujita, Kenichi
- Subjects
TAKOTSUBO cardiomyopathy ,COMPUTED tomography ,CORONARY arteries ,CARDIAC magnetic resonance imaging ,IODINE - Abstract
Cardiac computed tomography (CT) now plays an important role in emergency settings because of its accessibility and fast acquisition time, which cardiac magnetic resonance imaging (CMR) cannot match. Although cardiac CT was originally conceived for the assessment of the coronary artery tree, it has evolved to embrace several non-coronary applications. These include myocardial assessment, resulting in myocardial characterization comparable with that of CMR and cardiac CT for late enhancement imaging. In this report, we describe a patient with takotsubo cardiomyopathy who underwent a comprehensive assessment using cardiac CT. This technique enabled to identify the condition of the coronary arteries and to evaluate the four-dimensional left ventricular function and myocardial late iodine enhancement immediately. The information obtained was similar to that provided by CMR; however, cardiac CT is more practical than CMR in emergency settings. Comprehensive assessment by cardiac CT can be beneficial for a noninvasive evaluation of patients with suspected takotsubo cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. Non‐Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
- Author
-
Hirakawa, Kyoko, Takashio, Seiji, Marume, Kyohei, Yamamoto, Masahiro, Hanatani, Shinsuke, Yamamoto, Eiichiro, Sakamoto, Kenji, Izumiya, Yasuhiro, Kaikita, Koichi, Oda, Seitaro, Utsunomiya, Daisuke, Shiraishi, Shinya, Ueda, Mitsuharu, Yamashita, Taro, Yamashita, Yasuyuki, Ando, Yukio, and Tsujita, Kenichi
- Subjects
GENETIC mutation ,HYPERTROPHY ,AMYLOIDOSIS - Abstract
Aims: Mutant transthyretin (ATTRm) amyloidosis is a systemic disease caused by the deposition of amyloid fibrils derived from mutated transthyretin. Although cardiac involvement impacts the prognosis of patients with ATTRm amyloidosis, the incidence of cardiac events, such as bradyarrhythmia, ventricular tachycardia, and heart failure, has not been fully elucidated. The aim of this study was to evaluate the prognosis and predictors of clinical outcomes, including cardiac events, in patients with ATTRm amyloidosis in Japan. Methods and results: We evaluated 90 consecutive patients with ATTRm amyloidosis at Kumamoto University. ATTRm amyloidosis was diagnosed by the observation of both amyloid fibril deposition on tissue biopsy and a transthyretin mutation on sequential analysis. Sympathetic nerve activity was evaluated in 59 patients using 123‐iodine metaiodobenzylguanidine (123I‐MIBG) imaging. The endpoint was a composite of all‐cause death, hospitalization for heart failure, and implantation of a pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy defibrillator. Sixty‐seven patients had the Val30Met mutation (74%). The composite endpoint occurred in 23 patients (26%): all‐cause death (n = 6), hospitalization for worsening heart failure (n = 1), and implantation of an implantable cardioverter defibrillator (n = 6), cardiac resynchronization therapy defibrillator (n = 3), or pacemaker (n = 7). The 5‐year incident rate for clinical outcomes was 19%. In a multivariate Cox hazard analysis, age [hazard ratio (HR): 1.07, 95% confidence interval (95% CI): 1.01–1.12, P = 0.015], PQ interval (HR: 1.01, 95% CI: 1.00–1.02, P = 0.042), interventricular septum thickness in diastole (HR: 1.25, 95% CI: 1.09–1.42, P = 0.001), and non‐Val30Met mutation (HR: 4.31, 95% CI: 1.53–12.16, P = 0.006) were independent predictive factors of clinical outcomes. Kaplan–Meier analysis demonstrated a significantly higher probability of the composite endpoint in the non‐Val30Met group than in the Val30Met group (log‐rank test: P = 0.002) and in patients with left ventricular hypertrophy than in patients without left ventricular hypertrophy (log‐rank test: P < 0.001). In patients who underwent 123I‐MIBG imaging, a delayed heart‐to‐mediastinum (HM) ratio <1.6 was a significant predictive factor of the composite endpoint (HR: 4.98, 95% CI: 1.73–14.37, P = 0.003) in the univariate Cox hazard analyses. Kaplan–Meier curve analysis showed that a delayed HM ratio <1.6 was associated with a poor prognosis (log‐rank test: P = 0.001). Conclusions: Non‐Val30Met mutation, septal hypertrophy, and a delayed HM ratio are useful predictors of clinical outcomes in patients with ATTRm amyloidosis in Japan. These results suggest that it is important to evaluate cardiac involvement in terms of morphological (left ventricular hypertrophy) and functional (cardiac denervation) perspectives using echocardiography and 123I‐MIBG imaging, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation.
- Author
-
Uchiyama, Shinichiro, Atarashi, Hirotsugu, Inoue, Hiroshi, Kitazono, Takanari, Yamashita, Takeshi, Shimizu, Wataru, Ikeda, Takanori, Kamouchi, Masahiro, Kaikita, Koichi, Fukuda, Koji, Origasa, Hideki, and Shimokawa, Hiroaki
- Subjects
STROKE ,TRANSIENT ischemic attack ,ATRIAL fibrillation ,EMBOLISMS ,MEDICAL centers ,RIVAROXABAN - Abstract
The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treated with rivaroxaban (10 mg/day, 43.5%; 15 mg/day, 56.5%) were followed for a mean period of 897.1 ± 206.8 days with a high follow-up rate (99.7%). The primary prevention group comprised patients without history of ischemic stroke or TIA (n = 5546, 77.7%), and the secondary prevention group comprised those with history of ischemic stroke or TIA (n = 1595, 22.3%). In the primary and secondary prevention groups, the incidence rate of stroke or SE (primary efficacy endpoint) was 0.7 and 2.2%/year, respectively (P < 0.001), and the incidence rate of major bleeding (primary safety endpoint) was 1.2 and 1.5%/year, respectively (P = 0.132). For major bleeding events, the incidence rate of intracranial bleeding was 0.4 and 0.8%/year (P = 0.002) in the primary and secondary prevention groups, respectively. This sub-analysis of the EXPAND Study showed that the Japan-specific dosages of rivaroxaban were effective and safe in Japanese NVAF patients with and those without ischemic stroke or TIA in routine clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Sex- and Age-Based Disparities in Public Access Defibrillation, Bystander Cardiopulmonary Resuscitation, and Neurological Outcome in Cardiac Arrest.
- Author
-
Ishii, Masanobu, Tsujita, Kenichi, Seki, Tomohisa, Okada, Masafumi, Kubota, Kazumi, Matsushita, Kenichi, Kaikita, Koichi, Yonemoto, Naohiro, Tahara, Yoshio, and Ikeda, Takanori
- Published
- 2023
- Full Text
- View/download PDF
47. Late gadolinium enhancement on cardiac magnetic resonance imaging is associated with coronary endothelial dysfunction in patients with dilated cardiomyopathy.
- Author
-
Nakayama, Mina, Yamamuro, Megumi, Takashio, Seiji, Uemura, Tomoaki, Nakayama, Naoki, Hirakawa, Kyoko, Oda, Seitaro, Utsunomiya, Daisuke, Kaikita, Koichi, Hokimoto, Seiji, Yamashita, Yasuyuki, Morita, Yukiko, Kimura, Kazuo, Tamura, Kouichi, and Tsujita, Kenichi
- Subjects
HEART failure patients ,MYOCARDIAL infarction diagnosis ,ENDOTHELIUM diseases ,PATIENT acceptance of health care ,HEALTH outcome assessment - Abstract
Myocardial fibrosis and coronary endothelial dysfunction are important determinants of outcome in patients with heart failure. However, the relationship of these factors in patients with dilated cardiomyopathy (DCM) is not fully understood. This study aimed to investigate the relationship between endothelium-dependent coronary vasomotor abnormality and late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) in patients with DCM. We examined 38 consecutive patients with DCM. All patients underwent CMR and the acetylcholine (ACh) provocation test using cardiac catheterization. During the ACh provocation test, we sampled blood simultaneously from the coronary sinus and aortic root to compare lactate concentrations, and quantified coronary blood flow volume using an intracoronary Doppler-tipped guidewire. LGE was detected in 17 (44.7%) patients. The lactate extraction ratio (LER) in the ACh provocation test was significantly decreased in the LGE-positive group (before vs after ACh, 18.6 ± 13.6 vs − 13.3 ± 24.8%;
p < 0.001) and in the LGE-negative group (before vs after ACh, 14.2 ± 19.5 vs 3.3 ± 16.2%;p = 0.02). The rate of patients with an LER < 0% (indicating myocardial lactate production due to myocardial ischemia) was significantly higher in the LGE-positive group than in the LGE-negative group [12 (70.6%) vs 7 (33.3%);p = 0.02]. Multivariable logistic regression analysis showed that a post-ACh LER < 0% was a significant predictor of LGE positivity (odds ratio 7.75; 95% confidence interval 1.37-43.68;p = 0.02). In conclusion, ACh-provoked coronary vasomotor abnormality is associated with myocardial fibrosis in patients with DCM. These results suggest that coronary endothelial dysfunction is involved in myocardial fibrosis and worsening heart failure concomitant with DCM. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
48. Clinical significance of brachial-ankle pulse-wave velocity in patients with heart failure with preserved left ventricular ejection fraction.
- Author
-
Takanori Tokitsu, Eiichiro Yamamoto, Fumi Oike, Yoshihiro Hirata, Kenichi Tsujita, Megumi Yamamuro, Koichi Kaikita, Seiji Hokimoto, Tokitsu, Takanori, Yamamoto, Eiichiro, Oike, Fumi, Hirata, Yoshihiro, Tsujita, Kenichi, Yamamuro, Megumi, Kaikita, Koichi, and Hokimoto, Seiji
- Published
- 2018
- Full Text
- View/download PDF
49. Apical flow and wall motion dynamics in left ventricular outflow obstruction: a case report.
- Author
-
Misumi, Ikuo, Sato, Koji, Nagano, Miwa, Haba, Koichi, Ohba, Keisuke, Kaikita, Koichi, and Tsujita, Kenichi
- Published
- 2022
- Full Text
- View/download PDF
50. When Is the Optimal Timing of Surgical Intervention for Severe Functional Tricuspid Regurgitation?
- Author
-
Nakanishi, Nobuhiro, Ishii, Masanobu, Kaikita, Koichi, Okamoto, Ken, Izumiya, Yasuhiro, Yamamoto, Eiichiro, Takashio, Seiji, Hokimoto, Seiji, Fukui, Toshihiro, and Tsujita, Kenichi
- Subjects
TRICUSPID valve insufficiency ,HEART failure ,DISEASES in older women ,JAPANESE people ,HOSPITAL admission & discharge ,DISEASES - Abstract
Functional tricuspid regurgitation (TR) is a serious pathology to be noted for severe right heart failure (HF) and poor prognosis; however, the conventional assessment of TR has some limitations and the optimal timing of surgical intervention remains unclear. A 79-year-old Japanese female was admitted to our hospital to undergo cardiac surgery, because edema gradually got worse despite the increase in diuretics. She had a history of atrial fibrillation (AF) and chronic HF due to severe TR and had been treated with a furosemide for leg edema 4 years ago. A transthoracic echocardiogram (TTE), transesophageal echocardiogram, cardiac magnetic resonance imaging, and cardiac pool scintigraphy demonstrated severe functional TR with tricuspid annular dilation, insufficient tricuspid valve coaptation, and reduced right ventricular ejection fraction (EF) but preserved left ventricular EF. In addition, Swan-Ganz catheter study showed normal pulmonary arterial wedge pressure and mean pulmonary arterial pressure. Tricuspid ring annuloplasty was performed with MC3 ring. Postoperative TTE showed trivial TR, and she had no edema with normal sinus rhythm two months later. Annuloplasty to severe functional TR caused by tricuspid annular dilation due to AF dramatically improved right HF. Cardiologist should pay strict attention to the optimal timing of surgical intervention for TR. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.